Jose Luis Seoane
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jose Luis Seoane has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Nuria Raguer
Department of Neurophysiology, Hospital Universitari Vall d'Hebron (HUVH), Barcelona, Spain
16 shared publications M. Benito
8 shared publicationsM. Gratacos
7 shared publicationsJ. Gamez
5 shared publications- Margarida Gratacòs
Department of Clinical Neurophysiology. Vall d'Hebron University Hospital. Passeig de la Vall d'Hebron, 119 Barcelona, Spain
5 shared publications N. Lara
Hospital Universitari Vall d’Hebron, Clinical Neurophysiology, EMG Unit, Spain
5 shared publications
Latest Publications
- 26 August 2025
- Published by Elsevier in Clinical Neurophysiology
- Vol. 179, 2110989
Electrophysiological findings in immune checkpoint inhibitor-related neuromuscular events
- 26 August 2025
- Published by Elsevier in Clinical Neurophysiology
- Vol. 179, 2110989
Electrophysiological findings in immune checkpoint inhibitor-related neuromuscular events
- Open Access
- 16 May 2023
- Published by Elsevier in Clinical Neurophysiology
- Vol. 150, e151
N°249 – Electrophysiological findings in immune checkpoint inhibitor – Associated neurologic toxicity
- 16 May 2023
- Published by Elsevier in Clinical Neurophysiology
- Vol. 150, e151
Open AccessN°249 – Electrophysiological findings in immune checkpoint inhibitor – Associated neurologic toxicity
- Open Access
- 1 September 2022
- Published by Elsevier in Clinical Neurophysiology
- Vol. 141, S124
TH-146. Neuromuscular involvement in severe Covid-19 patients. Our experience in EMG unit of terciary hospital
- 1 September 2022
- Published by Elsevier in Clinical Neurophysiology
- Vol. 141, S124
Open AccessTH-146. Neuromuscular involvement in severe Covid-19 patients. Our experience in EMG unit of terciary hospital
- Open Access
- 7 July 2017
- Published by Wiley in Brain and Behavior
- Vol. 7 (8) , e00758
Long‐term safety and effectiveness of levodopa‐carbidopa intestinal gel infusion
Introduction: Levodopa‐carbidopa intestinal gel (LCIG) infusion has demonstrated to improve motor fluctuations. The aim of this study is to assess the long‐term safety and effectiveness of LCIG infusion in advanced Parkinson's disease (PD) patients with motor fluctuations and its effect in nonmotor symptoms.Methods: Adverse events (AE) and their management, clinical motor, and nonmotor aspects were assessed up to 10 years. Thirty‐seven patients were treated with LGIC; in three subsets of patients, specific batteries of tests were used to assess cognitive and behavior assessment for 6 months, quality of sleep for 6 months, and quality of life and caregiver burden for 1 year.Results: There was a high number of AE, but manageable, most of mild and moderate severity. All patients experienced significant improvement in motor fluctuations with a reduction in mean daily off time of 4.87 hr after 3 months (n = 37) to 6.25 hr after 9 years (n = 2). Diskynesias remained stables in 28 patients (75.7%) and improved in 5 patients (13.5%). There was no neuropsychological deterioration, but an improvement in attentional functions, voluntary motor control, and semantic fluency. Quality of sleep did not worsen, and there was an improvement in the subjective parameters, although overnight polysomnography did not change. There was a significant sustained improvement of 37% in PD‐Q39 after 3 months and to 1 year, and a significant reduction in caregiver burden of 10% after 3 months.Conclusion: LCIG infusion is a safe and efficacious treatment for the control of motor fluctuations, and for improvement or nonworsening of nonmotor aspects, long‐term sustained, and feasible for use in routine care.
- 7 July 2017
- Published by Wiley in Brain and Behavior
- Vol. 7 (8) , e00758
Open AccessLong‐term safety and effectiveness of levodopa‐carbidopa intestinal gel infusion
Introduction: Levodopa‐carbidopa intestinal gel (LCIG) infusion has demonstrated to improve motor fluctuations. The aim of this study is to assess the long‐term safety and effectiveness of LCIG infusion in advanced Parkinson's disease (PD) patients with motor fluctuations and its effect in nonmotor symptoms.Methods: Adverse events (AE) and their management, clinical motor, and nonmotor aspects were assessed up to 10 years. Thirty‐seven patients were treated with LGIC; in three subsets of patients, specific batteries of tests were used to assess cognitive and behavior assessment for 6 months, quality of sleep for 6 months, and quality of life and caregiver burden for 1 year.Results: There was a high number of AE, but manageable, most of mild and moderate severity. All patients experienced significant improvement in motor fluctuations with a reduction in mean daily off time of 4.87 hr after 3 months (n = 37) to 6.25 hr after 9 years (n = 2). Diskynesias remained stables in 28 patients (75.7%) and improved in 5 patients (13.5%). There was no neuropsychological deterioration, but an improvement in attentional functions, voluntary motor control, and semantic fluency. Quality of sleep did not worsen, and there was an improvement in the subjective parameters, although overnight polysomnography did not change. There was a significant sustained improvement of 37% in PD‐Q39 after 3 months and to 1 year, and a significant reduction in caregiver burden of 10% after 3 months.Conclusion: LCIG infusion is a safe and efficacious treatment for the control of motor fluctuations, and for improvement or nonworsening of nonmotor aspects, long‐term sustained, and feasible for use in routine care.
- 1 June 2011
- Published by Elsevier in Clinical Neurophysiology
- Vol. 122, S6-S7
W1.2 Multifocal motor neuropathy. Clinical and electrophysiological long term evolution in a group of patients
- 1 June 2011
- Published by Elsevier in Clinical Neurophysiology
- Vol. 122, S6-S7
W1.2 Multifocal motor neuropathy. Clinical and electrophysiological long term evolution in a group of patients
- 1 June 2011
- Published by Elsevier in Clinical Neurophysiology
- Vol. 122, S82
P5.19 Recurrent Guillain Barré syndrome: clinical and neurophysiological findings
- 1 June 2011
- Published by Elsevier in Clinical Neurophysiology
- Vol. 122, S82
P5.19 Recurrent Guillain Barré syndrome: clinical and neurophysiological findings
- 1 October 2010
- Published by Elsevier in Clinical Neurophysiology
- Vol. 121, S175-S176
P12-16 Neurophysiological characterization of Miller Fisher syndrome patients: Report of 10 patients
- 1 October 2010
- Published by Elsevier in Clinical Neurophysiology
- Vol. 121, S175-S176
P12-16 Neurophysiological characterization of Miller Fisher syndrome patients: Report of 10 patients
- 1 October 2010
- Published by Elsevier in Clinical Neurophysiology
- Vol. 121, S227
P21-4 Neurophysiological studies in a family with inherited primary erythromelalgia
- 1 October 2010
- Published by Elsevier in Clinical Neurophysiology
- Vol. 121, S227
P21-4 Neurophysiological studies in a family with inherited primary erythromelalgia
- 1 October 2010
- Published by Elsevier in Clinical Neurophysiology
- Vol. 121, S235-S236
P22-13 Axonal motor neuropathy in a patient with HIV infection mimicking motor neuron disease
- 1 October 2010
- Published by Elsevier in Clinical Neurophysiology
- Vol. 121, S235-S236
P22-13 Axonal motor neuropathy in a patient with HIV infection mimicking motor neuron disease